Later, this trial was re-analyzed for the possible predictive power of some prognostically relevant recurrent mutations in AML, namely, the NPM1, FLT3-ITD, FLT3 tyrosine kinase domain (TKD), MLL partial tandem duplication (PTD), and CEBPA mutations. This evidence concerns the gene CEBPA and acute myeloid leukemia.